FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2020172209> ?p ?o ?g. }

• W2020172209 endingPage "436" @default.
• W2020172209 startingPage "429" @default.
• W2020172209 abstract "Haploidentical SCT (HaploSCT) has been most commonly performed using a myeloablative, TBI-based preparative regimen; however, the toxicity with this approach remains very high. We studied the feasibility of a reduced-intensity conditioning regimen in a phase II clinical trial using fludarabine, melphalan and thiotepa and antithymocyte globulin (ATG) for patients with advanced hematological malignancies undergoing T-cell depleted HaploSCT. Twenty-eight patients were entered in the study. Engraftment with donor-derived hematopoiesis was achieved in 78% of patients after a median of 13 days. Six patients experienced primary graft failure, three out of four tested patients had donor-specific anti-HLA antibodies (DSA) (P=0.001). Toxicity included mostly infections. A total of 21 out of 22 patients with AML/myelodysplastic syndrome (MDS) achieved remission after transplant (16 with relapsed/refractory AML). Five out of the 12 patients (42%) with AML/MDS with <15% BM blasts survived long term as compared with none with more advanced disease (P=0.03). HaploSCT with this fludarabine, melphalan and thiotepa and ATG RIC is an effective, well-tolerated conditioning regimen for patients with AML/MDS with low disease burden at the time of transplant and allowed a high rate of engraftment in patients without DSA. Patients with overt relapse fared poorly and require novel treatment strategies." @default.
• W2020172209 created "2016-06-24" @default.
• W2020172209 creator A5005287531 @default.
• W2020172209 creator A5012676022 @default.
• W2020172209 creator A5015342719 @default.
• W2020172209 creator A5016268217 @default.
• W2020172209 creator A5016928938 @default.
• W2020172209 creator A5021095942 @default.
• W2020172209 creator A5033381380 @default.
• W2020172209 creator A5034264716 @default.
• W2020172209 creator A5040975741 @default.
• W2020172209 creator A5047522685 @default.
• W2020172209 creator A5048913229 @default.
• W2020172209 creator A5055885795 @default.
• W2020172209 creator A5069460930 @default.
• W2020172209 creator A5070096873 @default.
• W2020172209 creator A5071526808 @default.
• W2020172209 creator A5073053011 @default.
• W2020172209 creator A5074792956 @default.
• W2020172209 creator A5091083304 @default.
• W2020172209 date "2009-08-10" @default.
• W2020172209 modified "2023-10-16" @default.
• W2020172209 title "Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT" @default.
• W2020172209 cites W1479909146 @default.
• W2020172209 cites W1521169335 @default.
• W2020172209 cites W1585270289 @default.
• W2020172209 cites W1951884638 @default.
• W2020172209 cites W1966252771 @default.
• W2020172209 cites W1973171138 @default.
• W2020172209 cites W1982896128 @default.
• W2020172209 cites W1991691688 @default.
• W2020172209 cites W1997625619 @default.
• W2020172209 cites W2002595904 @default.
• W2020172209 cites W2019355056 @default.
• W2020172209 cites W2025561889 @default.
• W2020172209 cites W2027619061 @default.
• W2020172209 cites W2041055738 @default.
• W2020172209 cites W2046689400 @default.
• W2020172209 cites W2050921203 @default.
• W2020172209 cites W2067118929 @default.
• W2020172209 cites W2095348090 @default.
• W2020172209 cites W2108395794 @default.
• W2020172209 cites W2111951140 @default.
• W2020172209 cites W2120119492 @default.
• W2020172209 cites W2130040182 @default.
• W2020172209 cites W2147068163 @default.
• W2020172209 cites W2149131140 @default.
• W2020172209 cites W2159575415 @default.
• W2020172209 cites W2160666689 @default.
• W2020172209 cites W2200381048 @default.
• W2020172209 cites W2302206374 @default.
• W2020172209 cites W2317548431 @default.
• W2020172209 cites W2326259325 @default.
• W2020172209 cites W2334858305 @default.
• W2020172209 cites W4293241248 @default.
• W2020172209 doi "https://doi.org/10.1038/bmt.2009.189" @default.
• W2020172209 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4080627" @default.
• W2020172209 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19668237" @default.
• W2020172209 hasPublicationYear "2009" @default.
• W2020172209 type Work @default.
• W2020172209 sameAs 2020172209 @default.
• W2020172209 citedByCount "55" @default.
• W2020172209 countsByYear W20201722092012 @default.
• W2020172209 countsByYear W20201722092013 @default.
• W2020172209 countsByYear W20201722092014 @default.
• W2020172209 countsByYear W20201722092015 @default.
• W2020172209 countsByYear W20201722092016 @default.
• W2020172209 countsByYear W20201722092017 @default.
• W2020172209 countsByYear W20201722092018 @default.
• W2020172209 countsByYear W20201722092019 @default.
• W2020172209 countsByYear W20201722092020 @default.
• W2020172209 countsByYear W20201722092021 @default.
• W2020172209 countsByYear W20201722092022 @default.
• W2020172209 crossrefType "journal-article" @default.
• W2020172209 hasAuthorship W2020172209A5005287531 @default.
• W2020172209 hasAuthorship W2020172209A5012676022 @default.
• W2020172209 hasAuthorship W2020172209A5015342719 @default.
• W2020172209 hasAuthorship W2020172209A5016268217 @default.
• W2020172209 hasAuthorship W2020172209A5016928938 @default.
• W2020172209 hasAuthorship W2020172209A5021095942 @default.
• W2020172209 hasAuthorship W2020172209A5033381380 @default.
• W2020172209 hasAuthorship W2020172209A5034264716 @default.
• W2020172209 hasAuthorship W2020172209A5040975741 @default.
• W2020172209 hasAuthorship W2020172209A5047522685 @default.
• W2020172209 hasAuthorship W2020172209A5048913229 @default.
• W2020172209 hasAuthorship W2020172209A5055885795 @default.
• W2020172209 hasAuthorship W2020172209A5069460930 @default.
• W2020172209 hasAuthorship W2020172209A5070096873 @default.
• W2020172209 hasAuthorship W2020172209A5071526808 @default.
• W2020172209 hasAuthorship W2020172209A5073053011 @default.
• W2020172209 hasAuthorship W2020172209A5074792956 @default.
• W2020172209 hasAuthorship W2020172209A5091083304 @default.
• W2020172209 hasBestOaLocation W20201722092 @default.
• W2020172209 hasConcept C126322002 @default.
• W2020172209 hasConcept C141071460 @default.
• W2020172209 hasConcept C143998085 @default.
• W2020172209 hasConcept C2776694085 @default.
• W2020172209 hasConcept C2776755627 @default.

• next